The Medicines Company  

(Public, NASDAQ:MDCO)   Watch this stock  
Find more results for MDCO
+0.08 (0.15%)
Real-time:   10:39AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 53.46 - 54.01
52 week 29.48 - 54.01
Open 54.00
Vol / Avg. 90,789.00/1.72M
Mkt cap 3.83B
P/E     -
Div/yield     -
EPS -1.04
Shares 70.79M
Beta 0.50
Inst. own 118%
Feb 15, 2017
Q4 2016 Medicines Co Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -229.71% -71.82%
Operating margin -201.43% -86.56%
EBITD margin - -76.90%
Return on average assets -19.09% -12.06%
Return on average equity -43.43% -26.58%
Employees 614 -
CDP Score - -


United States - Map
+1-973-2906000 (Phone)
+1-973-6569898 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


The Medicines Company is a global biopharmaceutical company. The Company's marketed products include Angiomax (bivalirudin), Cleviprex (clevidipine) injectable emulsion, Ionsys (fentanyl iontophoretic transdermal system), Kengreal (cangrelor), Minocin (minocycline) for injection, and Orbactiv (oritavancin). Its pipeline of acute and intensive care hospital products in development include ABP-700, ALN-PCSsc, Carbavance and MDCO-216. It sells a ready to use formulation of Argatroban and has a portfolio of over 10 generic drugs, which is referred as acute care generic products. It sells over three acute care generic products, including midazolam, ondansetron and rocuronium. The Company's products include Angiomax, which is a direct thrombin inhibitor; Cleviprex, which is a calcium channel blocker; Ionsys, which is a patient-controlled analgesia system; Kengreal, which is an antiplatelet agent; Minocin IV, which is a tetracycline-class antibiotic, and Orbactiv, which is an antibiotic.

Officers and directors

Tony Kingsley President, Chief Operating Officer
Age: 50
Bio & Compensation  - Reuters
Clive A. Meanwell Ph.D. Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
William Bernard O'Connor Chief Financial Officer, Principal Accounting Officer
Age: 57
Bio & Compensation  - Reuters
Christopher T. Cox Executive Vice President, chief corporate development officer
Age: 51
Bio & Compensation  - Reuters
Jeffrey Frazier Executive Vice President, Chief Human Strategy Officer
Age: 53
Bio & Compensation  - Reuters
Stephen M. Rodin J.D. Senior Vice President, General Counsel, Secretary
Age: 40
Bio & Compensation  - Reuters
Fredric N. Eshelman Non-Executive Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
William W. Crouse Independent Director
Age: 73
Bio & Compensation  - Reuters
Alexander J. Denner Ph.D. Independent Director
Age: 46
Bio & Compensation  - Reuters
Robert J. Hugin Independent Director
Age: 61
Bio & Compensation  - Reuters